Article
Engineering the aveC gene to enhance the ratio of doramectin to its CHC-B2 analogue produced in Streptomyces avermitilis.
Biotechnology and bioengineering - 5 May 2003
Stutzman-Engwall Kim, Conlon Steve, Fedechko Ronald, Kaczmarek Frank, McArthur Hamish, Krebber Anke, Chen Yan, Minshull Jeremy, Raillard Sun Ai, Gustafsson Claes
Abstract excerpt
Avermectin and its analogues are produced by the actinomycete Streptomyces avermitilis and are major commercial products for parasite control in the fields of animal health, agriculture, and human infections. Historically, the avermectin analogue doramectin (CHC-B1), which is sold commercially as Dectomax is co-produced during fermentation with the undesired analogue CHC-B2 at a CHC-B2:CHC-B1 ratio of 1.6:1....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
